Skip to main content

Translating Neuroscience Discovery Into Patient Impact

We combine preclinical neuropharmacology and translational medicine to accelerate drug development for complex brain disorders. Our integrated platform—spanning validated disease models, advanced biomarker technologies, and clinical biocollection—delivers actionable insights that bridge bench to bedside.

From neuropsychiatric conditions like treatment-resistant depression to rare diseases such as CDKL5 Deficiency Disorder, we partner with pharma, biotech, and patient foundations to advance therapies that matter.

Deep Expertise Across CNS Therapeutic Areas

Neuropsychiatric
Diseases

  • Depression & Treatment-Resistant Depression
  • Anxiety Disorders
  • Schizophrenia

Neurodegenerative Diseases

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis (ALS)

Neuromuscular
Diseases

  • Charcot-Marie-Tooth Disease (CMT)

Neurodevelopmental Diseases

  • CDKL5 Deficiency Disorder (CDD)
  • Fragile X Syndrome (FXS)
  • Epilepsy & Seizure Disorders

Psychedelics and
Neuroplastogens

  • Classical psychedelics
  • Next-generation non-hallucinogenic neuroplastogens.

Neuropsychiatric Drug Discovery: Validated Models & Translational Biomarkers

Our preclinical neuropsychiatry platform combines validated rodent models, EEG biomarkers, and behavioral pharmacology to accelerate antidepressant, anxiolytic, and psychedelic drug development.

  • Major Depressive Disorder & Treatment-Resistant Depression Models: IFN-α rat, Wistar Kyoto rat (SSRI-resistant), Chronic Social Defeat mouse. Endpoints: Forced Swim Test, Sucrose Preference, Elevated Zero Maze. Validated with ketamine and psilocybin.
  • Anxiety & Schizophrenia Anxiety battery: Elevated Plus Maze, Open Field, Light-Dark Box, Marble Burying. Schizophrenia: Social Isolation model with EEG biomarkers (ASSR, Mismatch Negativity) and cognitive endpoints.
  • Psychedelics & Neuroplastogens Fully licensed for Schedule I compounds. Head Twitch Response, EEG readouts (gamma power, REM suppression), and neuroplasticity endpoints in rodent and human iPSC-derived neurons.
Explore Our Depression Models

Neurodegenerative Disease Research: Cross-Species Biomarker Validation

We accelerate neuroprotective drug development for Alzheimer’s, Parkinson’s, ALS, and MS through integrated biomarker platforms—Luminex 200, MSD QuickPlex SQ 120, and Li-Cor Odyssey CLx—validated across human, rodent, and canine samples.

  • Alzheimer’s & Parkinson’s Disease Biomarkers: Tau, pTau (T181, T217, T231), NfL, GFAP, α-synuclein. Human iPSC-derived neurons from Michael J. Fox Foundation lines. Aged Beagle model for cognitive decline studies.
  • ALS & Multiple Sclerosis Cross-species validation of NfL, NfH, TDP-43, and inflammatory panels. Clinical biocollection through San Raffaele Hospital collaboration enables direct preclinical-to-clinical translation.
Explore Our Biomarker Capabilities

Rare Disease & DEE Research: Integrated Translational Platforms

We #ThinkRare—partnering with patient foundations to advance therapies for Developmental and Epileptic Encephalopathies (DEEs). Our platform features in-house transgenic colonies, validated phenotyping, and the ELPIS study—the first international biomarker initiative in CDD.

  • CDKL5 Deficiency Disorder (CDD) Sole provider of a dedicated Cdkl5-KO seizure assessment platform. Comprehensive phenotyping: motor function, cognition, anxiety, naturalistic behaviors. Cross-species biomarkers (NfL, IL-10) validated in mice and patients.
  • Fragile X Syndrome (FXS) & Other DEEs Fmr1-KO and Scn1a-KO (Dravet) models with published behavioral and biomarker data. Seizure platforms: MEST, 6 Hz, PTZ, kindling models. EEG biomarkers aligned with clinical endpoints.
Explore Our DEE Platform